Summary
A bioRxiv preprint reports four genomic subtypes of mucosal melanoma and immune-cell patterns associated with disease progression and immunotherapy resistance. The findings point to TIM-3 as a possible research target, not an established treatment.
A bioRxiv preprint reports four genomic subtypes of mucosal melanoma and finds differences in the tumours’ immune environments compared with cutaneous melanoma. The researchers analysed genomic sequencing from 339 patients and profiled a broader cohort spanning primary and metastatic disease. They also report that a type of tumour-associated macrophage became more prominent in matched samples as disease progressed and immunotherapy resistance developed.
Mucosal melanoma arises in tissues lining parts of the body, rather than in the skin. The study describes it as a rare, aggressive melanoma subtype. Its findings may help researchers investigate why it behaves differently from cutaneous melanoma, but the work is a preprint and its proposed treatment target remains a research lead.
Four genomic groups, with distinct tumour features
The researchers classified the 339 patients into four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX and mucosal melanoma Triple WT. The groups were associated with different anatomical sites, while the researchers reported similar clinical outcomes across them.
The analysis also found that primary mucosal melanomas had greater genomic heterogeneity, ploidy and aneuploidy than cutaneous melanomas. Ploidy describes the amount of genetic material in a cell; aneuploidy refers to abnormal numbers of chromosomes. The mucosal tumours also showed a more dedifferentiated and proliferative pattern of gene activity. These differences describe tumour biology; the abstract does not identify a subtype-specific treatment.
Immune-cell patterns suggest a possible target
Compared with cutaneous melanoma, mucosal melanoma samples had fewer infiltrating T cells and more CD163-positive tumour-associated macrophages. In matched samples collected over time, these macrophages increased with disease progression and immunotherapy resistance. These are reported associations in the patient samples.
The researchers also describe interactions between CD163-positive macrophages and non-regulatory T cells involving GAL9 and TIM-3, and nominate TIM-3 blockade as a possible therapeutic strategy. That proposal follows from the immune profiling; the abstract reports no clinical test of TIM-3 blockade. Establishing whether it benefits patients would require treatment studies.
Together, the genomic and immune profiles offer a framework for studying mucosal melanoma as biologically distinct from its cutaneous counterpart. The findings are from a bioRxiv preprint and should be treated as preliminary research.